Equities researchers at Evercore assumed coverage on shares of Elevance Health (NYSE:ELV – Get Free Report) in a report issued on Wednesday, MarketBeat.com reports. The brokerage set an “in-line” rating and a $345.00 price target on the stock. Evercore’s price objective suggests a potential upside of 8.63% from the stock’s current price.
Several other equities research analysts have also recently weighed in on ELV. Wells Fargo & Company decreased their target price on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Barclays decreased their target price on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Guggenheim decreased their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research note on Thursday, January 29th. UBS Group set a $400.00 target price on Elevance Health in a research note on Thursday, January 29th. Finally, JPMorgan Chase & Co. boosted their target price on Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Twelve investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Elevance Health has an average rating of “Hold” and a consensus target price of $385.38.
Check Out Our Latest Stock Report on ELV
Elevance Health Stock Up 1.9%
Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities research analysts expect that Elevance Health will post 33.96 EPS for the current year.
Hedge Funds Weigh In On Elevance Health
A number of institutional investors have recently modified their holdings of the business. Foresight Global Investors Inc. increased its stake in Elevance Health by 5.6% in the 4th quarter. Foresight Global Investors Inc. now owns 865 shares of the company’s stock valued at $303,000 after buying an additional 46 shares during the period. Stance Capital LLC acquired a new position in Elevance Health in the 4th quarter valued at $1,358,000. World Investment Advisors increased its stake in Elevance Health by 6.0% in the 4th quarter. World Investment Advisors now owns 28,290 shares of the company’s stock valued at $9,917,000 after buying an additional 1,597 shares during the period. Larry Mathis Financial Planning LLC acquired a new position in Elevance Health in the 4th quarter valued at $736,000. Finally, Corient Private Wealth LLC increased its stake in Elevance Health by 12.2% in the 4th quarter. Corient Private Wealth LLC now owns 67,261 shares of the company’s stock valued at $23,579,000 after buying an additional 7,315 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.
More Elevance Health News
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: CMS finalized a 2.48% Medicare Advantage payment rate increase for 2027, and officials signaled an additional ~2.5% boost from risk‑adjustment changes — pushing the effective increase nearer to ~5%, which materially improves government program revenue outlook for ELV. Elevance Health Stock Soars After 2.48% Medicare Rate Increase
- Positive Sentiment: Bank of America updated its managed‑care outlook and raised its price target on Elevance, signaling analyst confidence that the CMS decision and structural dynamics support higher fair value. BofA Updates Managed Care Outlook, Raises Elevance Health (ELV) Price Target
- Positive Sentiment: Several analysts and outlets call the new rate a near‑term catalyst; some technical and valuation takes argue ELV is attractively priced after recent underperformance, supporting a buy case if fundamentals stabilize. Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good
- Neutral Sentiment: Earnings previews and analyst notes remind investors that Elevance still faces membership declines, higher benefit expense ratios and muted guidance — the CMS boost helps, but underlying operational trends will determine sustainability. Elevance Health earnings preview: What to expect
- Neutral Sentiment: Analysis pieces digging into the CMS change offer modeling details on how the rate and risk‑adjustment shifts flow to margins and EPS — useful for investors but dependent on enrollment and expense trends. Medicare Rates Up – What This Really Means For Elevance
- Negative Sentiment: Some analysts are cautious: Evercore ISI reinstated ELV at inline and asked whether the Medicare bounce is already priced in, implying upside may be limited if expectations are aggressive. Elevance Health Reinstated at Inline by Evercore ISI
- Negative Sentiment: Outlets urging a reassessment note ELV has slid ~27% over the last year and that valuation and operational headwinds (membership pressure, benefit costs) may still warrant caution despite the CMS news. Is It Time To Reassess Elevance Health (ELV) After A 27% One-Year Share Price Slide
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
See Also
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
